Instituto Gonçalo Moniz-Fundação Oswaldo Cruz, Bahia, Brazil; Programa de Pós-Graduação em Ciências da Saúde, Universidade Federal da Bahia, Bahia, Brazil; Serviço de Otorrinolaringologia do Hospital Santa Izabel/Santa Casa de Misericórdia da Bahia, Bahia, Brazil.
Serviço de Otorrinolaringologia do Hospital Santa Izabel/Santa Casa de Misericórdia da Bahia, Bahia, Brazil.
Clin Microbiol Infect. 2019 Apr;25(4):515.e5-515.e7. doi: 10.1016/j.cmi.2018.12.027. Epub 2019 Jan 4.
We aimed to detect Leishmania DNA carriage in nasal mucosa of individuals with cutaneous leishmaniasis (CL) caused by Leishmania (Viannia) braziliensis.
A cross-sectional study was performed in all individuals with CL without nasal lesions (n = 153) attended within 2 years in an endemic area of L. (Viannia) braziliensis in Bahia (Brazil). An otorhinolaryngologist assessed the clinical status of the nasal mucosa by anterior rhinoscopy and endoscopic examinations. Swab samples were collected for parasite DNA detection by PCR from all individuals before standard treatment for leishmaniasis. A second evaluation 3 months after treatment was performed to assess clinical outcomes.
Parasite DNA was detected in 7.8% (12/153) of clinically healthy nasal mucosa of individuals with CL. Interestingly, DNA was more frequently identified in individuals with more skin lesions (median 1.5, interquartile range (IQR) 1-3.5 versus 1.0, IQR 1-1.5; p 0.044), or larger injuries (median 2.7, IQR 2-3.8 versus 1.6, IQR 1-2.5; p 0.013). Additionally, the disease of those individuals with positive PCR evolved more frequently to unusual forms of leishmaniasis (recidiva cutis and disseminated) (45.5% (5/11) versus 11.5% (14/122); p 0.009), and required more cycles of treatment to reach clinical cure (median 2, IQR 1-4 versus 1, IQR 1-2; p 0.05).
These findings suggest an early parasite tropism to nasal mucosa in L. (Viannia) braziliensis infection and a clinical phenotype of CL cases associated with parasite DNA in nasal mucosa. Future studies should evaluate whether PCR of nasal swab samples could serve as a prognostic tool for individuals at risk of mucocutaneous leishmaniasis.
我们旨在检测巴西利什曼原虫引起的皮肤利什曼病(CL)患者鼻黏膜中的利什曼原虫 DNA 携带情况。
在巴西巴伊亚州利什曼原虫(Viannia)流行地区,对 2 年内所有无鼻病变的 CL 患者(n=153)进行了一项横断面研究。耳鼻喉科医生通过前鼻镜和内镜检查评估鼻黏膜的临床状况。对所有患者在标准抗利什曼病治疗前采集鼻拭子样本,通过 PCR 检测寄生虫 DNA。治疗 3 个月后进行第二次评估,以评估临床结果。
在 153 例临床健康的 CL 患者中,有 7.8%(12/153)的鼻黏膜中检测到寄生虫 DNA。有趣的是,DNA 更频繁地出现在有更多皮肤病变(中位数 1.5,四分位距(IQR)1-3.5 与 1.0,IQR 1-1.5;p=0.044)或更大损伤(中位数 2.7,IQR 2-3.8 与 1.6,IQR 1-2.5;p=0.013)的患者中。此外,PCR 阳性患者的疾病更常发展为不常见的利什曼病形式(复发皮肤利什曼病和播散性皮肤利什曼病)(45.5%(5/11)与 11.5%(14/122);p=0.009),并且需要更多的治疗周期才能达到临床治愈(中位数 2,IQR 1-4 与 1,IQR 1-2;p=0.05)。
这些发现表明巴西利什曼原虫感染时寄生虫早期向鼻黏膜的趋向性,以及与鼻黏膜中寄生虫 DNA 相关的 CL 病例的临床表型。未来的研究应评估鼻拭子样本的 PCR 是否可作为预测黏膜皮肤利什曼病风险个体的预后工具。